VanEck Pharmaceutical ETF
PPH
146 hedge funds and large institutions have $806M invested in VanEck Pharmaceutical ETF in 2025 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 41 increasing their positions, 45 reducing their positions, and 19 closing their positions.
105% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 19
42% more call options, than puts
Call options by funds: $7.55M | Put options by funds: $5.33M
15% more funds holding
Funds holding: 127 → 146 (+19)
13% more capital invested
Capital invested by funds: $713M → $806M (+$93.1M)
9% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 45
45.98% less ownership
Funds ownership: 114.6% → 68.62% (-46%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCIM
British Columbia Investment Management
Victoria,
British Columbia, Canada
|
+$67M |
| 2 |
Citigroup
New York
|
+$59.4M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$39.7M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$18.6M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$6.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$105M |
| 2 |
Morgan Stanley
New York
|
-$36.8M |
| 3 |
JP Morgan Chase
New York
|
-$24.7M |
| 4 |
RAM
Revere Asset Management
Dallas,
Texas
|
-$15.6M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$6.85M |
PPH Hedge Fund Activity: Q4 2025 in Review
146 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q4 2025, worth a combined $806M — up 13% from $713M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new PPH positions and 19 closed out — a net gain of 20 holders — while 41 added to existing stakes and 45 trimmed.
The largest buyer was British Columbia Investment Management, opening a new position worth an estimated $67M. The largest seller was Goldman Sachs, cutting an estimated $105M.
- 146 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q4 2025, up from 127 in Q3 2025.
- Funds reported $806M of VanEck Pharmaceutical ETF stock for Q4 2025, up 13% quarter-over-quarter.
- 39 funds opened new VanEck Pharmaceutical ETF positions in Q4 2025 and 19 closed out, a net change of +20 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q4 2025 was British Columbia Investment Management, an estimated $67M added.
- The largest VanEck Pharmaceutical ETF seller in Q4 2025 was Goldman Sachs, an estimated $105M sold.
Based on aggregated 13F filings for Q4 2025.